Drug Profile
BAY 872243
Alternative Names: BAY-87-2243Latest Information Update: 19 Jul 2016
Price :
$50
*
At a glance
- Originator Bayer HealthCare
- Class Antineoplastics; Small molecules
- Mechanism of Action Hypoxia-inducible factor-1 alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in Germany (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in Norway (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (PO, Tablet)